Discovery and application of FimH antagonists

Topics in Medicinal Chemistry

Volumn 12, Issue , 2014, Pages 123-168

  Gouin, Sébastien G ^a   Roos, Goedele ^b   Bouckaert, Julie ^c  

^a Centre National de la Recherche Scientifique   (France)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; BIPHENYL MANNOSIDE; GLYCAN; GLYCOPROTEIN; MANNOSE; MANNOSE BINDING LECTIN; MANNOSIDE; PROTEIN FIMH; PROTEIN INHIBITOR; THIAZOLYL ALPHA DELTA MANNOSE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM ADHERENCE; CONFORMATIONAL TRANSITION; CROHN DISEASE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG DETERMINATION; DRUG STRUCTURE; ESCHERICHIA COLI; FIMBRIA; GENE EXPRESSION REGULATION; HUMAN; HYDROPHOBICITY; IN VIVO STUDY; NONHUMAN; PROCESS OPTIMIZATION; QUANTUM CHEMISTRY; RECEPTOR DENSITY; SHEAR STRESS; STRUCTURE ANALYSIS; SURFACE PROPERTY; URINARY TRACT INFECTION;

EID: 84921520533     PISSN: 18622461     EISSN: 1862247X     Source Type: Book Series    
DOI: 10.1007/7355_2014_52     Document Type: Article

References (129)

1. Zhou G, Mo WJ, Sebbel P, Min G, Neubert TA, Glockshuber R, Wu XR, Sun TT, Kong XP (2001) Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. J Cell Sci 114(Pt 22):4095–4103
2. Eto DS, Jones TA, Sundsbak JL, Mulvey MA (2007) Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli. PLoS Pathog 3(7):e100
3. Thumbikat P, Berry RE, Zhou G, Billips BK, Yaggie RE, Zaichuk T, Sun TT, Schaeffer AJ, Klumpp DJ (2009) Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog 5(5):e1000415
4. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6(8):e1001042
5. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ (2003) Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301(5629):105–107
6. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, Footer MJ, Hultgren SJ (2004) Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 101(5):1333–1338
7. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ (2007) Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4(12):e329
8. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ (2000) Type 1 pilusmediated bacterial invasion of bladder epithelial cells. EMBO J 19(12):2803–2812
9. Hung CS, Bouckaert J, Hung DL, Pinkner J, Winberg C, Defusco A, Auguste CG, Strouse R, Langermann S, Waksman G, Hultgren SJ (2002) Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol Microbiol 44:903–915
10. Mulvey MA (2002) Adhesion and entry of uropathogenic Escherichia coli. Cell Microbiol 4(5):257–271
11. Wright KJ, Seed PC, Hultgren SJ (2007) Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 9(9):2230–2241
12. Chen SL, Hung CS, Pinkner JS, Walker JN, Cusumano CK, Li Z, Bouckaert J, Gordon JI, Hultgren SJ (2009) Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc Natl Acad Sci U S A 106(52):22439–22444
13. Mysorekar IU, Hultgren SJ (2006) Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 103(38):14170–14175
14. Mysorekar IU, Isaacson-Schmid M, Walker JN, Mills JC, Hultgren SJ (2009) Bone morphogenetic protein 4 signaling regulates epithelial renewal in the urinary tract in response to uropathogenic infection. Cell Host Microbe 5(5):463–475
15. Mysorekar IU, Mulvey MA, Hultgren SJ, Gordon JI (2002) Molecular regulation of urothelial renewal and host defenses during infection with uropathogenic Escherichia coli. J Biol Chem 277(9):7412–7419
16. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ (2012) Hostpathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 36(3):616–648
17. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6(8)
18. Geerlings SE (2008) Urinary tract infections in patients with diabetes mellitus: epidemiology, pathogenesis and treatment. Int J Antimicrob Agents 31(Suppl 1):S54–S57
19. Geerlings SE, Meiland R, van Lith EC, Brouwer EC, Gaastra W, Hoepelman AIM (2002) Adherence of type 1-fimbriated Escherichia coli to uroepithelial cells – more in diabetic women than in control subjects. Diabetes Care 25(8):1405–1409
20. Geerlings SE, Beerepoot MA, Prins JM (2014) Prevention of recurrent urinary tract infections in women: antimicrobial and nonantimicrobial strategies. Infect Dis Clin North Am 28(1): 135–147
21. Eshdat Y, Ofek I, Yashouv-Gan Y, Sharon N, Mirelman D (1978) Isolation of a mannosespecific lectin from Escherichia coli and its role in the adherence of the bacteria to epithelial cells. Biochem Biophys Res Commun 85(4):1551–1559
22. Firon N, Ofek I, Sharon N (1983) Carbohydrate specificity of the surface lectins of Escherichia coli, Klebsiella pneumoniae and Salmonella typhimurium. Carbohydr Res 120: 235–249
23. Firon N, Ofek I, Sharon N (1984) Carbohydrate-binding sites of the mannose-specific fimbrial lectins of enterobacteria. Infect Immun 43(3):1088–1090
24. Sharon N (1987) Bacterial Lectins, cell-cell recognition and infectious disease. FEBS Lett 217:145–157
25. Egge H, Michalski JC, Strecker G (1982) Heterogeneity of urinary oligosaccharides from mannosidosis: mass spectrometric analysis of permethylated Man9, Man8, and Man7 derivatives. Arch Biochem Biophys 213(1):318–326
26. Firon N, Ofek I, Sharon N (1982) Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli. Biochem Biophys Res Commun 105(4):1426–1432
27. Wellens A, Garofalo C, Nguyen H, Van Gerven N, Slattegard R, Hernalsteens JP, Wyns L, Oscarson S, De Greve H, Hultgren S, Bouckaert J (2008) Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS One 3(4):e2040
28. Minion FC, Abraham SN, Beachey EH, Goguen JD (1986) The genetic determinant of adhesive function in type 1 fimbriae of Escherichia coli is distinct from the gene encoding the fimbrial subunit. J Bacteriol 165:1033–1036
29. Abraham SN, Sun D, Dale JB, Beachey EH (1988) Conservation of the D-mannose-adhesion protein among type 1 fimbriated members of the family enterobactericeae. Nature 336: 682–684
30. Bouckaert J, Mackenzie J, de Paz JL, Chipwaza B, Choudhury D, Zavialov A, Mannerstedt K, Anderson J, Pierard D, Wyns L, Seeberger PH, Oscarson S, De Greve H, Knight SD (2006) The affinity of the FimH fimbrial adhesin is receptor-driven and quasiindependent of Escherichia coli pathotypes. Mol Microbiol 61(6):1556–1568
31. Duncan MJ, Mann EL, Cohen MS, Ofek I, Sharon N, Abraham SN (2005) The distinct binding specificities exhibited by enterobacterial type 1 fimbriae are determined by their fimbrial shafts. J Biol Chem 280(45):37707–37716
32. Rosenstein IJ, Stoll MS, Mizuochi T, Childs RA, Hounsell EF, Feizi T (1988) New type of adhesive specificity revealed by oligosaccharide probes in Escherichia coli from patients with urinary tract infection. Lancet 2(8624):1327–1330
33. Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slattegard R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H (2005) Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 55(2):441–455
34. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N (1987) Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal cells. Infect Immun 55:472–476
35. Wellens A, Lahmann M, Touaibia M, Vaucher J, Oscarson S, Roy R, Remaut H, Bouckaert J (2012) The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH. Biochemistry 51(24):4790–4799
36. Durka M, Buffet K, Iehl J, Holler M, Nierengarten JF, Taganna J, Bouckaert J, Vincent SP (2011) The functional valency of dodecamannosylated fullerenes with Escherichia coli FimH-towards novel bacterial antiadhesives. Chem Commun 47(4):1321–1323
37. Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B (2012) Antiadhesion therapy for urinary tract infections–a balanced PK/PD profile proved to be key for success. J Med Chem 55(10):4700–4713
38. Han Z, Pinkner JS, Ford B, Chorell E, Crowley JM, Cusumano CK, Campbell S, Henderson JP, Hultgren SJ, Janetka JW (2012) Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides. J Med Chem 55(8):3945–3959
39. Roos G, Wellens A, Touaibia M, Yamakawa N, Geerlings P, Roy R, Wyns L, Bouckaert J (2013) Validation of reactivity descriptors to assess the aromatic stacking within the tyrosine gate of FimH. ACS Med Chem Lett 4(11):1085–1090
40. Barnich N, Darfeuille-Michaud A (2010) Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by adherent-invasive E. coli. Virulence 1 (4):281–282
41. Serafini-Cessi F, Monti A, Cavallone D (2005) N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. Glycoconj J 22 (7–9):383–394
42. Xie B, Zhou G, Chan SY, Shapiro E, Kong XP, Wu XR, Sun TT, Costello CE (2006) Distinct glycan structures of uroplakins Ia and Ib: structural basis for the selective binding of FimH adhesin to uroplakin Ia4. J Biol Chem 281(21):14644–14653
43. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 127 (2):412–421
44. Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A (2007) CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 117(6):1566–1574
45. Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H (2009) Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 462(7270):226–230
46. Bernon C, Carre Y, Kuokkanen E, Slomianny MC, Mir AM, Krzewinski F, Cacan R, Heikinheimo P, Morelle W, Michalski JC, Foulquier F, Duvet S (2011) Overexpression of Man2C1 leads to protein underglycosylation and upregulation of endoplasmic reticulumassociated degradation pathway. Glycobiology 21(3):363–375
47. Bilyy R, Stoika R (2007) Search for novel cell surface markers of apoptotic cells. Autoimmunity 40(4):249–253
48. Bilyy RO, Shkandina T, Tomin A, Munoz LE, Franz S, Antonyuk V, Kit YY, Zirngibl M, Furnrohr BG, Janko C, Lauber K, Schiller M, Schett G, Stoika RS, Herrmann M (2012) Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J Biol Chem 287(1):496–503
49. Bilyy R, Bouckaert J (2011) FimH from uropathogenic Escherichia coli binds to the blebs of apoptotic cells. Sepsis 4(1):96–97
50. Eto DS, Gordon HB, Dhakal BK, Jones TA, Mulvey MA (2008) Clathrin, AP-2, and the NPXY-binding subset of alternate endocytic adaptors facilitate FimH-mediated bacterial invasion of host cells. Cell Microbiol 10(12):2553–2567
51. Dhakal BK, Mulvey MA (2009) Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem 284(1):446–454
52. Thankavel K, Shah AH, Cohen MS, Ikeda T, Lorenz RG, Curtiss R, Abraham SN (1999) Molecular basis for the enterocyte tropism exhibited by Salmonella typhimurium type 1 fimbriae. J Biol Chem 274(9):5797–5809
53. Sokurenko EV, Chesnokova V, Doyle RJ, Hasty DL (1997) Diversity of the Escherichia coli type 1 fimbrial lectin. Differential binding to mannosides and uroepithelial cells. J Biol Chem 272(28):17880–17886
54. Lonardi E, Moonens K, Buts L, de Boer AR, Olsson JD, Weiss MWS, Fabre E, Guerardel Y, Deelder AM, Oscarson S, Wuhrer M, Bouckaert J (2013) Structural sampling of glycan interaction profiles reveals mucosal receptors for fimbrial adhesins of enterotoxigenic Escherichia coli. Biology 2:894–917
55. Thomas WE, Trintchina E, Forero M, Vogel V, Sokurenko EV (2002) Bacterial adhesion to target cells enhanced by shear force. Cell 109(7):913–923
56. Thomas W, Forero M, Yakovenko O, Nilsson L, Vicini P, Sokurenko E, Vogel V (2006) Catch-bond model derived from allostery explains force-activated bacterial adhesion. Biophys J 90(3):753–764
57. Pereverzev YV, Prezhdo OV, Forero M, Sokurenko EV, Thomas WE (2005) The two-pathway model for the catch-slip transition in biological adhesion. Biophys J 89(3): 1446–1454
58. Le Trong I, Aprikian P, Kidd BA, Forero-Shelton M, Tchesnokova V, Rajagopal P, Rodriguez V, Interlandi G, Klevit R, Vogel V, Stenkamp RE, Sokurenko EV, Thomas WE (2010) Structural basis for mechanical force regulation of the adhesin FimH via finger traplike beta sheet twisting. Cell 141(4):645–655
59. Nilsson LM, Thomas WE, Trintchina E, Vogel V, Sokurenko EV (2006) Catch bondmediated adhesion without a shear threshold – trimannose versus monomannose interactions with the FimH adhesin of Escherichia coli. J Biol Chem 281(24):16656–16663
60. Nilsson LM, Thornas WE, Sokurenko EV, Vogel V (2006) Elevated shear stress protects Escherichia coli cells adhering to surfaces via catch bonds from detachment by soluble inhibitors. Appl Environ Microbiol 72(4):3005–3010
61. Aprikian P, Tchesnokova V, Kidd B, Yakovenko O, Yarov-Yarovoy V, Trinchina E, Vogel V, Thomas W, Sokurenko E (2007) Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose. J Biol Chem 282(32):23437–23446
62. Tchesnokova V, Aprikian P, Yakovenko O, Larock C, Kidd B, Vogel V, Thomas W, Sokurenko E (2008) Integrin-like allosteric properties of the catch-bond forming FimH adhesin of E. coli. J Biol Chem 283(12):7823–7833
63. Le Trong I, Aprikian P, Kidd BA, Thomas WE, Sokurenko EV, Stenkamp RE (2010) Donor strand exchange and conformational changes during E. coli fimbrial formation. J Struct Biol 172(3):380–388
64. Gong M, Makowski L (1992) Helical structure of P pili from Escherichia Coli. J Mol Biol 228:735–742
65. Miller E, Garcia T, Hultgren S, Oberhauser AF (2006) The mechanical properties of E. coli type 1 pili measured by atomic force microscopy techniques. Biophys J 91:3848–3856
66. Forero M, Yakovenko O, Sokurenko EV, Thomas WE, Vogel V (2006) Uncoiling mechanics of Escherichia coli type I fimbriae are optimized for catch bonds. PLoS Biol 4(9):1509–1516
67. Bullitt E, Makowski L (1995) Structural polymorphism of bacterial adhesion pili. Nature 373:164–167
68. Snyder JA, Haugen BJ, Lockatell CV, Maroncle N, Hagan EC, Johnson DE, Welch RA, Mobley HLT (2005) Coordinate expression of fimbriae in uropathogenic Escherichia coli. Infect Immun 73(11):7588–7596
69. Snyder JA, Lloyd AL, Lockatell CV, Johnson DE, Mobley HLT (2006) Role of phase variation of type 1 fimbriae in a uropathogenic Escherichia coli cystitis isolate during urinary tract infection. Infect Immun 74(2):1387–1393
70. Lindberg S, Xia Y, Sonden B, Goransson M, Hacker J, Uhlin BE (2008) Regulatory interactions among adhesin gene systems of uropathogenic Escherichia coli. Infect Immun 76(2):771–780
71. Abraham JM, Freitag CS, Clements JR, Eisenstein BI (1985) An invertible element of DNA controls phase variation of type 1 fimbriae of Escherichia coli. Proc Natl Acad Sci U S A 82: 5724–5727
72. Muller CM, Aberg A, Straseviciene J, Emody L, Uhlin BE, Balsalobre C (2009) Type 1 fimbriae, a colonization factor of uropathogenic Escherichia coli, are controlled by the metabolic sensor CRP-cAMP. PLoS Pathog 5(2):e1000303
73. Schneeberger C, Kazemier BM, Geerlings SE (2014) Asymptomatic bacteriuria and urinary tract infections in special patient groups: women with diabetes mellitus and pregnant women. Curr Opin Infect Dis 27(1):108–114
74. Munera D, Hulgren SJ, Fernandez LA (2007) Recognition of the N-terminal lectin domain of FimH adhesin by the usher FimD is required for type 1 pilus biogenesis. Mol Microbiol 64: 333–346
75. Phan G, Remaut H, Wang T, Allen WJ, Pirker KF, Lebedev A, Henderson NS, Geibel S, Volkan E, Yan J, Kunze MB, Pinkner JS, Ford B, Kay CW, Li H, Hultgren SJ, Thanassi DG, Waksman G (2011) Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 474(7349):49–53
76. Munera D, Palomino C, Fernández LA (2008) Specific residues in the N-terminal domain of FimH stimulate type 1 fimbriae assembly in Escherichia coli following the initial binding of the adhesin to FimD usher. Mol Microbiol 69(4):911–925
77. Abraham SN, Goguen JD, Beachey EH (1988) Hyperadhesive mutant of type 1 fimbriated Escherichia coli associated with the formation of FimH organelles (fimbriosomes). Infect Immun 56:1023–1029
78. Schwartz DJ, Kalas V, Pinkner JS, Chen SL, Spaulding CN, Dodson KW, Hultgren SJ (2013) Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc Natl Acad Sci U S A 110:15530–15537
79. Dennis JW, Brewer CF (2013) Density-dependent lectin-glycan interactions as a paradigm for conditional regulation by posttranslational modifications. Mol Cell Proteomics 12(4): 913–920
80. Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, Dennis JW (2007) Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129(1):123–134
81. Eto DS, Mulvey MA (2007) Flushing bacteria out of the bladder. Nat Med 13(5):531–532
82. Chabre YM, Roy R (2008) Recent trends in glycodendrimer syntheses and applications. Curr Top Med Chem 8(14):1237–1285
83. Almant M, Moreau V, Kovensky J, Bouckaert J, Gouin SG (2011) Clustering of Escherichia coli type-1 fimbrial adhesins by using multimeric heptyl alpha-D-mannoside probes with a carbohydrate core. Chem. Eur. J. 17(36):10029–10038
84. Bouckaert J, Li Z, Xavier C, Almant M, Caveliers V, Lahoutte T, Weeks SD, Kovensky J, Gouin SG (2013) Heptyl alpha-D-mannosides grafted on a beta-cyclodextrin core to interfere with Escherichia coli adhesion: an in vivo multivalent effect. Chem Eur J 19(24):7847–7855
85. Langermann S, Palaszynski S, Barnhart M, Auguste G, Pinkner JS, Burlein J, Barren P, Koenig S, Leath S, Jones CH, Hultgren SJ (1997) Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276(5312):607–611
86. Roberts JA, Marklund BI, Ilver D, Haslam D, Kaack MB, Baskin G, Louis M, Mollby R, Winberg J, Normark S (1994) The Gal alpha(1–4) Gal-specific tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur in the normal urinary tract. Proc Natl Acad Sci U S A 91:11889–11893
87. Aronson M, Medalia O, Schori L, Mirelman D, Sharon N, Ofek I (1979) Prevention of colonization of the urinary-tract by blocking bacterial adherence with methyl-alpha-Dmannopyranoside. Israel J Med Sci 15(1):88
88. Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, Henderson JP, Janetka JW, Hultgren SJ (2011) Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 3(109):109-115
89. Knight SD, Bouckaert J (2009) Structure, function, and assembly of type 1 fimbriae. Top Curr Chem 288:67–107
90. Brument S, Sivignon A, Dumych TI, Moreau N, Roos G, Guerardel Y, Chalopin T, Deniaud D, Bilyy RO, Darfeuille-Michaud A, Bouckaert J, Gouin SG (2013) Thiazolylaminomannosides as potent anti-adhesives of type 1 piliated Escherichia coli isolated from Crohn’s disease patients. J Med Chem 56(13):5395–5406
91. Schwardt O, Rabbani S, Hartmann M, Abgottspon D, Wittwer M, Kleeb S, Zalewski A, Smiesko M, Cutting B, Ernst B (2011) Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem 19(21):6454–6473
92. Touaibia M, Wellens A, Glinschert A, Shiao TC, Wang Q, Papadopoulos A, Bouckaert J, Roy R (2014) O - and C -linked mannopyranosides to chemically disarm uropathogenic Escherichia coli by targeting their type-1 fimbriae mediated adhesion. To be published
93. Pang L, Kleeb S, Lemme K, Rabbani S, Scharenberg M, Zalewski A, Schadler F, Schwardt O, Ernst B (2012) FimH antagonists: structure-activity and structure–property relationships for biphenyl alpha-D-mannopyranosides. ChemMedChem 7:1404–1422
94. Han Z, Pinkner JS, Ford B, Obermann R, Nolan W, Wildman SA, Hobbs D, Ellenberger T, Cusumano CK, Hultgren SJ, Janetka JW (2010) Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J Med Chem 53(12):4779–4792
95. Wermuth CG, Ganellin CR, Lindberg P, Mitscher LA (1998) Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998). Pure Appl Chem 70(5):1129–1143
96. Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M, Haug M, Schwardt O, Ernst B (2012) Antiadhesion therapy for urinary tract infections-a balanced PK/PD profile proved to be key for success. J Med Chem 55(10):4700–4713
97. Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Luthi C, Scharenberg M, Bezencon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B (2010) FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 53(24):8627–8641
98. Lee YC, Lee RT (1995) Carbohydrate-protein interactions: basis of glycobiology. Acc Chem Res 28:321–327
99. Hartmann M, Lindhorst TK (2011) The bacterial lectin FimH, a target for drug discovery - carbohydrate inhibitors of type 1 fimbriae-mediated bacterial adhesion. Eur J Org Chem 2011:3583–3609
100. Touaibia M, Roy R (2007) Glycodendrimers as anti-adhesion drugs against type 1 fimbriated E. coli uropathogenic infections. Mini Rev Med Chem 7(12):1270–1283
101. Sperling O, Fuchs A, Lindhorst TK (2006) Evaluation of the carbohydrate recognition domain of the bacterial adhesin FimH: design, synthesis and binding properties of mannoside ligands. Org Biomol Chem 4(21):3913–3922
102. Abgottspon D, Rölli G, Hosch L, Steinhuber A, Jiang X, Schwardt O, Cutting B, Smiesko M, Jenal U, Ernst B, Trampuz A (2010) Development of an aggregation assay to screen FimH antagonists. J Microbiol Methods 82:249–255
103. Boettner B (2013) Debugging Crohn’s disease. SciBX 6(26):1–2
104. Deniaud D, Julienne K, Gouin SG (2011) Insights in the rational design of synthetic multivalent glycoconjugates as lectin ligands. Org Biomol Chem 9(4):966–979
105. Lundquist JJ, Toone EJ (2002) The cluster glycoside effect. Chem Rev 102(2):555–578
106. Chabre YM, Roy R (2010) Design and creativity in synthesis of multivalent neoglycoconjugates. Adv Carbohydr Chem Biochem 63:165–393
107. Lindhorst TK, Kieburg C, Krallmann-Wenzel U (1998) Inhibition of the type 1 fimbriaemediated adhesion of Escherichia coli to erythrocytes by multiantennary alpha-mannosyl clusters: the effect of multivalency. Glycoconj J 15(6):605–613
108. Nagahori N, Lee RT, Nishimura S, Pag C D, Roy R, Lee YC (2002) Inhibition of adhesion of type 1 fimbriated Escherichia coli to highly mannosylated ligands. Chembiochem 3(9): 836–844
109. Touaibia M, Wellens A, Shiao TC, Wang Q, Sirois S, Bouckaert J, Roy R (2007) Mannosylated G(0) dendrimers with nanomolar affinities to Escherichia coli FimH. ChemMedChem 2(8):1190–1201
110. Gouin SG, Wellens A, Bouckaert J, Kovensky J (2009) Synthetic multimeric heptyl mannosides as potent antiadhesives of uropathogenic Escherichia coli. ChemMedChem 4 (5):749–755
111. Vanwetswinkel S, Volkov AN, Sterckx YG, Garcia-Pino A, Buts L, Vranken WF, Bouckaert J, Roy R, Wyns L, van Nuland NA (2014) Study of the structural and dynamic effects in the FimH adhesin upon alpha-d-heptyl mannose binding. J Med Chem 57(4):1416–1427
112. Disney MD, Zheng J, Swager TM, Seeberger PH (2004) Detection of bacteria with carbohydrate-functionalized fluorescent polymers. J Am Chem Soc 126(41):13343–13346
113. Klebe G (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11(13–14):580–594
114. Billiet L, Geerlings P, Messens J, Roos G (2012) The thermodynamics of thiol sulfenylation. Free Radic Biol Med 52(8):1473–1485
115. Roos G, Wellens A, Touaibia M, Yamakawa N, Geerlings P, Roy R, Wyns L, Bouckaert J (2013) Validation of reactivity descriptors to assess the aromatic stacking within the tyrosine gate of FimH. Med Chem Lett 4:1085–1090
116. Yilmazer ND, Korth M (2013) Comparison of molecular mechanics, semi-empirical quantum mechanical, and density functional theory methods for scoring protein-ligand interactions. J Phys Chem B 117(27):8075–8084
117. Bickelhaupt FM, Baerends EJ (2000) Kohn-Sham density functional theory: predicting and understanding chemistry. In: Lipkowitz KB, Boyd DB (eds) Reviews in computational chemistry, vol 15. Wiley-VCH, New York, pp 1–86
118. Krapp A, Bickelhaupt FM, Frenking G (2006) Orbital overlap and chemical bonding. Chem Eur J 12(36):9196–9216
119. Lepík M, Rězáě J, Kolář M, Pecina A, Hobza P, Fanfrlík J (2013) The semiempirical quantum mechanical scoring function for in silico drug design. Chempluschem 78:921–931
120. Genheden S, Mikulskis P, Hu L, Kongsted J, Soderhjelm P, Ryde U (2011) Accurate predictions of nonpolar solvation free energies require explicit consideration of bindingsite hydration. J Am Chem Soc 133(33):13081–13092
121. Chattaraj PK, Roy DR, Geerlings P, Torrent-Succarrat M (2007) Local hardness: a critical account. Theor Chem Acc 118:923–930
122. Bercowitz M, Parr RG (1985) On the concept of local hardness in chemistry. J Am Chem Soc 107:6811–6814
123. Parr RG, Pearson RG (1983) Absolute hardness: companion parameter to absolute electronegativity. J Am Chem Soc 105:7512–7516
124. Buckingham AD (1967) Permanent and induced molecular moments and long-range intermolecular forces. Adv Chem Phys 12:107
125. Mignon P, Loverix S, Steyaert J, Geerlings P (2005) Influence of the pi-pi interaction on the hydrogen bonding capacity of stacked DNA/RNA bases. Nucleic Acids Res 33(6):1779–1789
126. Mignon P, Loverix S, Geerlings P (2004) Influence of stacking on hydrogen bonding: quantum chemical study on pyridine-benzene model complexes. J Phys Chem A 108: 6038–6044
127. Wheeler SE (2011) Local nature of substituent effects in stacking interactions. J Am Chem Soc 133(26):10262–10274
128. Raju RK, Bloom JWG, Wheeler SE (2013) Broad transferability os substituent effects in p-stacking interactions provide new insight into their origin. J Chem Theory Comput 9: 3479–3490
129. Eid S, Zalewski A, Smiesko M, Ernst B, Vedani A (2013) A molecular-modeling toolbox aimed at bridging the gap between medicinal chemistry and computational sciences. Int J Mol Sci 14(1):684–700